Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week.

23 May 2014

Studies show mobile phones can cause allergic contact dermatitis in both children and adults

Studies have identified mobile phones and related devices as sources of metal sensitization and potential causes of allergic contact dermatitis (ACD).

21 May 2014

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US.

20 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

CVD risk factors may differ between men and women with type 2 diabetes, shows study

Type 2 diabetes greatly increases a person's risk of developing cardiovascular disease (CVD). A new study showing that cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women is published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

16 May 2014

Nanogel heals burn wounds faster

Researchers at the Institute of Bioengineering and Nanotechnology have developed a nanogel that can accelerate the healing of burn wounds to minimize the risk of infection and scarring. The technology is based on IBN’s proprietary self-assembling ultrashort peptide technology, which are short sequences of amino acids.

16 May 2014

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

The breakthrough, published in the journal Nature Materials, could offer an easier way of detecting pathogenic bacteria outside of a clinical setting and could be particularly important for the developing world, where access to more sophisticated laboratory techniques is often limited.

13 May 2014

Perrigo receives final approval from FDA for azelastine hydrochloride nasal spray ANDA

Perrigo Company plc announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%).

12 May 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging aims at the visualization of molecules or molecular events that occur at the cellular level. Clearly it also allows the possibility of looking inside the biochemical pathway at the cellular level and therefore enables us to look at the onset of diseases well before they are resolved into structural change.

From Bruker BioSpin Group 12 May 2014

Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release.

12 May 2014

Research on laser assisted drug delivery selected for April 2014 issue of LSM

Research conducted by Lindsay R. Sklar, M.D., Christopher T. Burnett, M.D., F.A.A.D., Jill S. Waibel, M.D., F.A.A.D., Ronald L. Moy, M.D., F.A.A.D., and David M. Ozog, M.D., F.A.A.D., was selected as Editor’s Choice for the April 2014 issue of Lasers in Surgery and Medicine.

9 May 2014

Form of baclofen works better at treating narcolepsy

Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice.

8 May 2014

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

8 May 2014

FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company), announced today the availability of the FDA-cleared BD MAX Enteric Bacterial Panel for use on the BD MAX System.

From BD (Becton, Dickinson and Company) 7 May 2014

USPTO issues three new patents to Discovery Laboratories

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent and Notices of Allowance for patents covering critical aspects of its KL4 surfactant and drug delivery technology platform.

7 May 2014

Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Phillips-Medisize Corporation today announced that it has entered into a definitive agreement under which Golden Gate Capital will acquire the Company from funds managed by Kohlberg & Company, L.L.C.

7 May 2014

Cambrex sales decrease by 11.2% in first quarter 2014

Cambrex Corporation reports results for the first quarter ended March 31, 2014.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.

30 Apr 2014

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2014.

29 Apr 2014

Drug Delivery News and Research

Further Reading

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Studies show mobile phones can cause allergic contact dermatitis in both children and adults

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

CVD risk factors may differ between men and women with type 2 diabetes, shows study

Nanogel heals burn wounds faster

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

Perrigo receives final approval from FDA for azelastine hydrochloride nasal spray ANDA

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Research on laser assisted drug delivery selected for April 2014 issue of LSM

Form of baclofen works better at treating narcolepsy

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

FDA-cleared BD MAX Enteric Bacterial Panel now available to detect bacterial pathogens

USPTO issues three new patents to Discovery Laboratories

Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Cambrex sales decrease by 11.2% in first quarter 2014

Biotech to the rescue

Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Pharmaron’s drug conjugates platform from idea to XDC eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo